Reversible dilated cardiomyopathy related to amphotericin B therapy

Patrick J. Danaher; Michael K. Cao; Gregory M. Anstead; Matthew J. Dolan; Caroline C. DeWitt

doi:10.1093/jac/dkg472

Reversible dilated cardiomyopathy related to amphotericin B therapy

Patrick J. Danaher^*, Michael K. Cao, Gregory M. Anstead, Matthew J. Dolan, Caroline C. DeWitt

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.

Original language	English
Pages (from-to)	115-117
Number of pages	3
Journal	Journal of Antimicrobial Chemotherapy
Volume	53
Issue number	1
DOIs	https://doi.org/10.1093/jac/dkg472
State	Published - Jan 2004
Externally published	Yes

Keywords

Coccidioides immitis
Coccidioidomycosis
Posaconazole

Access to Document

10.1093/jac/dkg472

Cite this

@article{aacae1040e534cf8a519e3ec23a86858,

title = "Reversible dilated cardiomyopathy related to amphotericin B therapy",

abstract = "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.",

keywords = "Coccidioides immitis, Coccidioidomycosis, Posaconazole",

author = "Danaher, {Patrick J.} and Cao, {Michael K.} and Anstead, {Gregory M.} and Dolan, {Matthew J.} and DeWitt, {Caroline C.}",

note = "Funding Information: We gratefully acknowledge financial support of this research by the National Institutes of Health (Grant #GM 073645-01 to K.L. S-R) and the National Science Foundation (Grant DMR-0079647 to O.W.).",

year = "2004",

month = jan,

doi = "10.1093/jac/dkg472",

language = "English",

volume = "53",

pages = "115--117",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

number = "1",

}

TY - JOUR

T1 - Reversible dilated cardiomyopathy related to amphotericin B therapy

AU - Danaher, Patrick J.

AU - Cao, Michael K.

AU - Anstead, Gregory M.

AU - Dolan, Matthew J.

AU - DeWitt, Caroline C.

N1 - Funding Information: We gratefully acknowledge financial support of this research by the National Institutes of Health (Grant #GM 073645-01 to K.L. S-R) and the National Science Foundation (Grant DMR-0079647 to O.W.).

PY - 2004/1

Y1 - 2004/1

N2 - We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.

AB - We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.

KW - Coccidioides immitis

KW - Coccidioidomycosis

KW - Posaconazole

UR - http://www.scopus.com/inward/record.url?scp=0346025669&partnerID=8YFLogxK

U2 - 10.1093/jac/dkg472

DO - 10.1093/jac/dkg472

M3 - Article

C2 - 14657095

AN - SCOPUS:0346025669

SN - 0305-7453

VL - 53

SP - 115

EP - 117

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Reversible dilated cardiomyopathy related to amphotericin B therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this